BioRestorative Therapies to Participate in Upcoming UBS and Maxim Group Investor Events

Rhea-AI Summary

BioRestorative Therapies (NASDAQ: BRTX), a regenerative medicine company specializing in stem cell-based therapies, has announced its participation in two upcoming investor events in October 2024:

1. UBS Virtual Organ Restoration and Cell Therapy Day: CEO Lance Alstodt will engage in a fireside chat with UBS analyst Ash Verma on October 15, 2024, at 1:00 p.m. ET.

2. 2024 Maxim Healthcare Virtual Summit: Alstodt will participate in another fireside chat with Jason McCarthy, Ph.D., Maxim Group's Head of Biotechnology Research, on October 17, 2024, at 11:00 a.m. ET.

These events provide opportunities for BRTX to showcase its innovative stem cell-based therapies and products to potential investors and industry experts.

MELVILLE, N.Y., Oct. 10, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, announces the following investor events in October:

• UBS Virtual Organ Restoration and Cell Therapy Day: Lance Alstodt, BioRestorative’s Chief Executive Officer, will participate in a fireside chat with UBS’ SMID-cap Biotech & Specialty Pharma Analyst, Ash Verma, on October 15, 2024 at 1:00 p.m. ET.
• 2024 Maxim Healthcare Virtual Summit: Mr. Alstodt will participate in a fireside chat with Maxim Group’s Head of Biotechnology Research, Jason McCarthy, Ph.D., on Thursday, October 17 2024 at 11:00 a.m. ET.

About BioRestorative Therapies, Inc.

BioRestorative (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. As described below, our two core clinical development programs relate to the treatment of disc/spine disease and metabolic disorders, and we have also recently begun offering BioCosmeceutical products:

• Disc/Spine Program (brtxDISC^™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease.

• Metabolic Program (ThermoStem^®): We are developing cell-based therapy candidates to target obesity and metabolic disorders using brown adipose (fat) derived stem cells (“BADSC”) to generate brown adipose tissue (“BAT”), as well as exosomes secreted by BADSC. BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes. BADSC secreted exosomes may also impact weight loss.

• BioCosmeceuticals: We operate a commercial BioCosmeceutical platform. Our current commercial product, formulated and manufactured using our cGMP ISO-7 certified clean room, is a cell-based secretome containing exosomes, proteins and growth factors. This proprietary biologic serum has been specifically engineered by us to reduce the appearance of fine lines and wrinkles and bring forth other areas of cosmetic effectiveness. Moving forward, we also intend to explore the potential of expanding our commercial offering to include a broader family of cell-based biologic aesthetic products and therapeutics via Investigational New Drug (IND)-enabling studies, with the aim of pioneering U.S. Food and Drug Administration (FDA) approvals in the emerging BioCosmeceuticals space.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

CONTACT:

Stephen Kilmer
Investor Relations
Direct: (646) 274-3580
Email: skilmer@biorestorative.com

FAQ

What investor events is BioRestorative Therapies (BRTX) participating in during October 2024?

BioRestorative Therapies (BRTX) is participating in two investor events in October 2024: the UBS Virtual Organ Restoration and Cell Therapy Day on October 15, and the 2024 Maxim Healthcare Virtual Summit on October 17.

When is BioRestorative Therapies (BRTX) participating in the UBS Virtual Organ Restoration and Cell Therapy Day?

BioRestorative Therapies (BRTX) is participating in the UBS Virtual Organ Restoration and Cell Therapy Day on October 15, 2024, at 1:00 p.m. ET.

Who will represent BioRestorative Therapies (BRTX) at the upcoming investor events?

Lance Alstodt, BioRestorative Therapies' Chief Executive Officer, will represent the company at both the UBS and Maxim Group investor events in October 2024.

What is the focus of BioRestorative Therapies (BRTX) as a company?

BioRestorative Therapies (BRTX) is a regenerative medicine innovator focused on developing stem cell-based therapies and products.